论文部分内容阅读
目的 :观察纳洛酮预防中枢性应激性溃疡的疗效。方法 :10 1例中枢神经系统损伤的病人随机分为 3组 :纳洛酮组 37例给予纳洛酮 0 .0 2mg·kg- 1,iv ,q 12h ;奥美拉唑组给予奥美拉唑 4 0mg ,iv ,qd ;硫糖铝组 2 9例给予硫糖铝 1.0 g ,po ,qid ,均连用 2wk。观察应激性溃疡出血的发生率及死亡率。结果 :纳洛酮组的应激性溃疡出血及死亡发生率 (5 % ,3% )显著低于硫糖铝组 (31% ,14% ) ,差异有非常显著或显著意义 (P <0 .0 1或P <0 .0 5 ) ;奥美拉唑组 (6 % ,3% )与硫糖铝组 (31% ,14% )比较 ,差异有显著意义 (P <0 .0 5 ) ;纳洛酮组 (5 % ,3% )与奥美拉唑组 (6 % ,3% )比较 ,差异无显著意义 (P >0 .0 5 )。结论 :纳洛酮可有效的降低中枢性应激性溃疡的发生率
Objective: To observe the efficacy of naloxone in preventing central stress ulcer. Methods: One hundred and ten patients with central nervous system injury were randomly divided into three groups: Naloxone group was given naloxone 0. 02 mg · kg-1, iv, q for 12 hours; Omeprazole group was given omeprazole Azole 4 0mg, iv, qd; sucralfate group 29 cases given sucralfate 1.0 g, po, qid, were used even 2wk. To observe the incidence of stress ulcer bleeding and mortality. Results: The incidence of stress ulcer bleeding and death in naloxone group (5%, 3%) was significantly lower than that in sucralfate group (31%, 14%). The difference was significant or significant (P <0. 0 1 or P <0.05). The difference was significant (P <0.05) between the omeprazole group (6%, 3%) and the sucralfate group (31%, 14% There was no significant difference between naloxone group (5%, 3%) and omeprazole group (6%, 3%) (P> 0.05). Conclusion: Naloxone can effectively reduce the incidence of central stress ulcer